Allergen Research Secures $80,000,000 Series B Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=dd857874-0681-4642-8a98-689f77fe0875
Date
3/12/2015
Company Name
Allergen Research
Mailing Address
2000 Alameda de las Pulgas San Mateo, CA 94403 USA
Company Description
Allergen Research Corporation (ARC) develops treatments to protect children with food allergies from the threatening consequences of accidental exposure. ARC was founded in 2011 in partnership with Food Allergy Research & Education (FARE), the nation’s leading nonprofit focused on food allergies.
Website
http://www.allergenresearch.com
Transaction Type
Venture Equity
Transaction Amount
$80,000,000
Transaction Round
Series B
Proceeds Purposes
ARC will use the proceeds to fund the upcoming Phase 3 clinical trial of ARC’s lead product, AR 101, a standardized, pharmaceutical-grade peanut protein formulation for treating peanut allergy via characterized oral desensitization immunotherapy (CODIT). The company also plans to begin clinical trials for treatment of egg and milk allergies in the coming year.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor